Ageing: The Biggest Unmet Medical Need of the 21st Century

Introduction

Advancements in medical and life sciences over the past century have helped human-kind in eliminating smallpox and almost eradicating polio with the development of vaccines. It was the rapid development of the mRNA vaccine that countered the COVID-19 pandemic and saved millions of lives in 2020. Drug development research has reduced HIV-AIDS from a lethal disease to a manageable one. With advancements in targeted therapies, multiple cancers have been transformed into manageable diseases.

And yet the overall burden of disease keeps climbing. In 2021, the Global Burden of Disease (GBD) Study, reported that total disability-adjusted life years (DALYs) lost globally rose from 2.63 billion in 2010 to 2.99 billion in 2021. The major cause for this was population ageing.

Aging is associated with almost all chronic diseases, namely Cancer. Cardiovascular disease. Type 2 diabetes. Neurodegeneration. Osteoarthritis. Chronic kidney disease. Reports have found that these diseases are caused by age-related cellular deterioration, or are made dramatically harder to treat in an aged body.

Why Aging Is Medicine's Largest Unmet Need

The numbers are difficult to absorb. The global population aged 60 and over is projected to double to 2.1 billion by 2050, with the cohort aged 80 and over expected to triple. According to the World Health Organization, chronic conditions already affect 60% of adults aged 60 and over globally, with cardiovascular diseases alone accounting for 45% of deaths in this group.

The economic consequences are equally stark. The global cost of aging; spanning healthcare, pensions, and long-term care, is projected to reach $15 trillion annually by 2030, up from approximately $7 trillion in 2020. For health systems already stretched by post-pandemic recovery and rising co-morbidity, these projections are not abstract forecasts.

Rethinking Ageing: From Inevitable to Treatable

For most of medical history, aging was categorized as a natural process rather than a pathological one, something to be managed at the margins but not meaningfully modified. That view has shifted.

The emergence of geroscience, the scientific discipline studying the mechanistic relationship between aging biology and age-related disease, has reframed the question. Biologically, aging is now understood as the progressive accumulation of molecular and cellular damage across nine hallmarks: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication.

Critically, these hallmarks are not simply markers of age. They are mechanistic drivers of disease. When mitochondrial function declines, inflammatory signaling increases, metabolic regulation fails, and neurodegenerative risk rises across multiple conditions. When senescent cells accumulate, they release a cocktail of pro-inflammatory cytokines, the senescence-associated secretory phenotype (SASP), that degrades surrounding tissue and fuels pathology in organs far from the source.

This understanding produced a paradigm-shifting hypothesis: target the biology of aging, and you may delay the onset of many diseases at once. The geroscience community has shifted from asking "what causes this disease?" to asking "what causes the biology that causes all these diseases?" The distinction is more than semantic. It is strategic.

From Treating Diseases to Targeting Aging

The traditional pharmaceutical model follows a linear logic: identify a disease, find a molecular target, develop a drug, run a trial, seek indication-specific approval. This model has delivered extraordinary medicines. It has also delivered a pipeline that, by design, treats conditions one at a time, often in patients whose biology has already deteriorated past the point where intervention is most effective.

The geroscience alternative inverts this. Instead of waiting for a disease to declare itself and then treating it, the model proposes intervening in the biological processes that make disease inevitable. The target is not a tumour, a plaque, or a dysfunctional receptor. The target is the cell's biological age.

Several existing drug classes are already demonstrating cross-disease effects that support this logic. SGLT2 inhibitors and GLP-1 receptor agonists, originally developed for type 2 diabetes, have shown clinically meaningful benefits in heart failure, chronic kidney disease, and, in emerging data, metabolic neurodegeneration. These drugs are not simply treating those diseases. They appear to be modifying shared upstream biological drivers. The distinction matters for how pharma should think about trial design, labeling, and market positioning.

This same cross-disease logic is what's driving AI-native biotechs to rethink drug discovery from the ground up. See how foundation models trained on biological sequences are compressing R&D timelines.

→ Read: How AI-Native Biotech Companies Are Rewriting The Rules Of Drug Discovery

The New Wave of Longevity Therapeutics

The longevity therapeutics pipeline is no longer a theoretical construct. Several mechanistically distinct approaches have now reached clinical evaluation.

Senolytics are agents that selectively clear senescent cells from tissues. Unity Biotechnology's UBX1325 (foselutoclax) completed Phase 2b evaluation in 2025, with results from the ASPIRE trial in diabetic macular edema demonstrating non-inferiority to aflibercept, providing meaningful proof of concept for senolytic clinical translation. Separately, the combination of Dasatinib and Quercetin is in Phase 1/2 trials targeting both Alzheimer's disease and pulmonary fibrosis, directly reflecting the cross-disease potential of senolytic intervention.

mTOR pathway modulation is among the most evidence-backed approaches in longevity biology. Rapamycin extends healthy lifespan in multiple model organisms. The PEARL trial, a Phase 2 study evaluating low-dose rapamycin in healthy aging adults, has generated early signals of immune rejuvenation and reduced systemic inflammation, supporting interest in mTOR inhibition as a genuine gerotherapeutic.

NAD+ metabolism represents another active clinical frontier. Intracellular NAD+ levels decline progressively with age, impairing sirtuin activity, mitochondrial function, and DNA repair capacity. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are being evaluated as NAD+ precursors in multiple trials, though translating metabolic improvements into clinically meaningful endpoints remains an open and active challenge.

Partial cellular reprogramming: the transient expression of Yamanaka transcription factors to restore epigenetic youthfulness without inducing full pluripotency, remains the most ambitious frontier in the field. David Sinclair's laboratory at Harvard demonstrated in a landmark 2023 work in Cell that targeted reprogramming can restore visual function in aged mice, a proof of principle that biological age is, in at least some contexts, reversible.

Measuring Ageing: The Rise of Biological Clocks

One of the most consequential recent developments in geroscience is the ability to measure biological age independently of chronological age. This matters enormously for pharma: you cannot run a clinical trial on an intervention that targets ageing without a validated way to measure whether ageing has actually changed.

Epigenetic clocks, pioneered by Steve Horvath at UCLA, use DNA methylation patterns at specific CpG sites to generate a biological age estimate that correlates with disease risk, mortality, and functional decline more accurately than birth year alone. Newer generation clocks including GrimAge and DunedinPACE go further, measuring not just biological age but the rate at which an individual is ageing, which is arguably more clinically relevant for intervention trials.

Proteomic clocks are emerging as a complementary approach. Irina Conboy's group and others have demonstrated that plasma protein signatures can reliably capture biological age across multiple tissue types. These multi-analyte approaches may ultimately provide more actionable clinical data than single-analyte DNA methylation measures, particularly for trials with diverse ageing endpoints.

For pharma, the strategic importance of these tools is direct: they offer potential surrogate endpoints that could make longevity clinical trials feasible within realistic timeframes, rather than requiring decades-long follow-up to capture mortality or disease incidence outcomes.

Challenges Holding the Field Back

The opportunities in geroscience are real. So are the obstacles, and intellectual honesty requires naming them.

The most fundamental is regulatory. Ageing is not classified as a disease by the FDA or EMA. Any drug targeting ageing biology must currently seek approval through a specific disease indication, macular degeneration, Alzheimer's, pulmonary fibrosis, even when the mechanism is broadly gerotherapeutic. The TAME trial (Targeting Aging with Metformin), sponsored by the American Federation for Aging Research, is attempting to establish a regulatory precedent by testing metformin against a composite endpoint spanning multiple age-related diseases simultaneously.

Biomarker validation remains incomplete. Biological clocks are compelling research tools, but none has been formally accepted by regulators as a validated surrogate endpoint for a longevity intervention. Until that changes, every longevity trial must be designed around disease-specific outcomes, constraining design flexibility and extending timelines.

Clinical trial duration is a structural problem with no clean solution. Age-related diseases develop over decades. Demonstrating that an intervention genuinely delays their onset requires long-term follow-up that pharmaceutical economics struggle to accommodate. Adaptive trial designs and disease-agnostic platform trials may offer partial workarounds.

Equity and access deserve a place in this conversation. Longevity interventions developed for and priced for high-income markets will not reach the 80% of the world's older people who will, by 2050, live in low- and middle-income countries. The field must build a global access strategy into its development model, rather than retrofitting one after approval.

Pharma's Biggest Opportunity Since Precision Medicine?

Despite these challenges, the commercial logic for pharma's engagement with ageing biology is increasingly difficult to ignore.

Consider the cross-indication opportunity. A drug that genuinely modifies biological ageing does not treat one disease; it reduces risk across many. The addressable market is not a single indication with a defined patient population. It is the cumulative disease burden of an ageing global population, across every therapeutic area simultaneously. By most analyses, no larger commercial opportunity exists in medicine today.

Consider also the pipeline diversification angle. Companies that established early positions in precision oncology, gene therapy, and GLP-1 biology generated disproportionate long-term returns as those categories matured from scientific novelty to standard of care. Geroscience is at an analogous inflection point: the fundamental biology is established, early clinical signals are positive, and the regulatory pathway, while complex is beginning to be mapped.

Investment patterns reflect this logic. Funding for longevity therapeutics has grown substantially over the past five years, with major pharma companies moving beyond passive observation to active partnerships, licensing, and acquisitions of longevity-focused biotechs.^[7] The question is not whether this category will matter. It is who will be positioned when it does.

recision oncology and GLP-1 biology already proved this pattern — early pipeline bets paying off big. See the 11 deals shaping where pharma is placing its next-generation bets.

→ Read: Pharma Mergers and Acquisitions 2026: Top 11 Deals You Need to Know

What's Coming Next?

The near-term pipeline will be shaped by three converging developments.

Partial cellular reprogramming will move from preclinical validation into first-in-human studies within the next two to three years. The ability to restore youthful epigenetic states in specific tissues, without dedifferentiating cells, could represent the most transformative advance in regenerative medicine since the development of iPSC technology.

AI-designed gerotherapeutics will accelerate candidate identification. Several biotech companies are already using foundation models trained on multi-omics ageing datasets to design novel small molecules targeting individual ageing hallmarks. The pace of target-to-candidate compression is unlike anything seen through conventional medicinal chemistry.

Integrated longevity diagnostics will begin to define a new healthcare delivery model, one in which biological age is routinely measured, tracked over time, and used to guide preventive pharmacological intervention before clinical disease manifests. For pharma, this creates both a new distribution challenge and an opportunity to build early relationships with a growing class of longevity-focused healthcare providers.

Conclusion

The Global Burden of Disease data makes an argument that is difficult to dispute. A healthcare system built to treat diseases one at a time, in patients whose biology has already substantially deteriorated, is approaching the structural limits of its own model.^[1] The ageing of the global population is not simply a threat to be managed. It is a biological reality that medicine must begin to address at its root.

Geroscience offers a different proposition: that the same cellular and molecular processes driving one age-related disease are driving many, and that intervening in those processes early may delay them all. The scientific foundation is now sound. The early clinical evidence is encouraging. The regulatory and measurement infrastructure is being actively built.

The question for pharmaceutical strategy is no longer whether ageing biology will become a major therapeutic category. The field has moved well past that debate. The question is at what speed, through which mechanisms, and with what level of early commitment companies choose to position themselves for what may prove to be the most consequential medical frontier of the coming decades.